Literature DB >> 26893290

Toxic effects of melphalan, topotecan and carboplatin on retinal pigment epithelial cells.

Daniela Süsskind1, Ulrike Hagemann1, Merle Schrader1,2, Kai Januschowski1, Sven Schnichels1, Sabine Aisenbrey1,2.   

Abstract

PURPOSE: Clinical evidence of retinal pigment epithelium (RPE) alterations after intra-arterial (IAC) and intravitreal chemotherapy (IViC) of retinoblastoma has been reported. We, therefore, investigated the cellular toxic effects of melphalan, topotecan and carboplatin on the RPE in a cell culture model.
METHODS: The effects of melphalan, carboplatin and topotecan on ARPE19 cell morphology were examined by phase contrast microscopy. Cell proliferation was quantified by BrdU incorporation, cell viability studied via MTS assays, and cell densities were estimated by Crystal Violet staining, and apoptosis induction studied via caspase 3/7-activity assays after a 24-hr incubation period. Staurosporine, media without fetal bovine serum, diluents of melphalan, carboplatin and topotecan were applied as positive and negative controls, respectively.
RESULTS: We observed a concentration-dependent increase in the number and size of gaps in the ARPE19 cell layer with each drug. There was a significant decrease in proliferative activity and cell viability of RPE cells as well as an increase in apoptosis after 24 hrs culture in media supplemented with melphalan and topotecan. Carboplatin had comparable effects on cell proliferation and cell viability; however, no significant apoptotic impacts were observed. The three cytostatic drugs had insignificant effects on cell density measurements.
CONCLUSIONS: Morphological monitoring and toxicity assays indicate a direct toxic effect of melphalan and the other two cytostatic drugs on ARPE19 cells. Thus, a direct toxic effect of melphalan in vivo after IAC or IViC on the RPE seems probable and may explain the clinical and angiographic RPE alterations observed in some retinoblastoma patients.
© 2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  chemotherapy; intra-ocular tumour; retinal pigment epithelium; retinoblastoma; toxicity

Mesh:

Substances:

Year:  2016        PMID: 26893290     DOI: 10.1111/aos.12990

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  8 in total

1.  Atypical Retinal Pigment Epithelial Hyperplasia and Glial Proliferation Masquerading as Progressive Recurrent Retinoblastoma: A Case Report Review and Clinicopathologic Correlation.

Authors:  Emily Zolfaghari; Jonathan W Kim; Subramanian Krishnan; Patricia Chévez-Barrios; Jesse L Berry
Journal:  Ocul Oncol Pathol       Date:  2017-09-16

2.  Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach.

Authors:  Anthony B Daniels; Michael T Froehler; Amy H Nunnally; Janene M Pierce; Ivan Bozic; Cameron A Stone; Pranav R Santapuram; Yuankai K Tao; Kelli L Boyd; Lauren E Himmel; Sheau-Chiann Chen; Liping Du; Debra L Friedman; Ann Richmond
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-03-01       Impact factor: 4.799

3.  Development of an enzyme‑linked immunosorbent assay for camptothecin.

Authors:  Liting Yan; Xiang Nan; Cunzheng Zhang; Haifang Wang; Xiaoyan Huang; Jun Hu; Yingqian Liu
Journal:  Mol Med Rep       Date:  2019-06-05       Impact factor: 2.952

Review 4.  Treatment of Retinoblastoma: What Is the Latest and What Is the Future.

Authors:  Paula Schaiquevich; Jasmine H Francis; María Belén Cancela; Angel Montero Carcaboso; Guillermo L Chantada; David H Abramson
Journal:  Front Oncol       Date:  2022-04-01       Impact factor: 5.738

5.  Targeting HMGA protein inhibits retinoblastoma cell proliferation.

Authors:  Akilandeswari Balachandran; Ajit Zambre; Jagjot Singh Kainth; Lakshmi Dhevi Nagarajha Selvan; Sowmya Parameswaran; Zahra Afrasiabi; Subramanian Krishnakumar; Raghuraman Kannan; Anandhi Upendran
Journal:  RSC Adv       Date:  2018-09-07       Impact factor: 4.036

6.  Ocular safety of repeated intravitreal injections of Carboplatin and Digoxin: A preclinical study on the healthy rabbits.

Authors:  Alireza Khodabande; Fariba Ghassemi; Fahimeh Asadi Amoli; Hamid Riazi-Esfahani; Raziyeh Mahmoudzadeh; Mohammad Mehrpour; Niloufar Valipour
Journal:  Pharmacol Res Perspect       Date:  2021-08

7.  Sclero-conjunctival ischaemia secondary to intra-arterial chemotherapy for retinoblastoma.

Authors:  Lisa McAnena; Zishan Naeem; Catriona Duncan; Fergus Robertson; Mandeep S Sagoo; M Ashwin Reddy
Journal:  Am J Ophthalmol Case Rep       Date:  2020-01-30

8.  Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma.

Authors:  Yacoub A Yousef; Mays Al Jboor; Mona Mohammad; Mustafa Mehyar; Mario D Toro; Rashed Nazzal; Qusai H Alzureikat; Magdalena Rejdak; Mutasem Elfalah; Iyad Sultan; Robert Rejdak; Maysa Al-Hussaini; Ibrahim Al-Nawaiseh
Journal:  Front Pharmacol       Date:  2021-07-12       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.